anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Adenosine
Trial phase: Phase 3
ATC code: C01EB10 | J05AB03 | S01AD06
SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 7
Group description: Giving adenosine Ising the recommended AHA two syringe method

Adenosine: A vial of adenosine with 6mg
Eligibility criteria:
Inclusion Criteria:

Svt
normal blood pressure
normal mentation
Give consent

Exclusion Criteria:

recent coffee
Allergy to adenosine
Asthma
cardiac operations
Intervention: Nifedipine
Trial phase: Phase 4
ATC code: C07FB03 | C08CA05 | C08CA55 | C08GA01
SMILES: COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-]
Sex: Female
Age groups: Adult
Healthy volunteers: No
Participants at risk: 110
Group description: Oral administration of 30mg Nifedipine XL q24 hours until delivery

Nifedipine 30 MG: Nifedipine XL is a long-acting medication used to lower blood pressure. The investigators want to learn whether women who receive the study drug will experience fewer severe-range blood pressure readings, and therefore need fewer intravenous (IV) medications to safely lower blood pressure.
Eligibility criteria:
Inclusion Criteria:

Women aged 18-45 with a viable single or twin intrauterine pregnancy between 22 0/7 and 41 6/7 weeks gestation based on the best obstetric estimate by The American College of Obstetricians and Gynecologists (ACOG) criteria.
Diagnosis of preeclampsia with severe features with decision made to induce labor. The patient may or may not have already received acute treatment for severe blood pressures.

Exclusion Criteria:

Known allergy or adverse reaction to Nifedipine or any medical condition where Nifedipine is contraindicated, such as galactose intolerance, severe gastrointestinal (GI) structure, and GI hypomotility disorder.
Currently receiving Nifedipine XL as part of hypertension management prior to induction of labor
Participation in another trial that affects the primary outcome without prior approval
Physician/provider or patient refusal
Participation in this trial in a prior pregnancy
Triplet or higher order pregnancy
Intervention: Bemnifosbuvir hemisulfate
Trial phase: Phase 2
SMILES: CNc1nc(N)nc2c1ncn2C1OC(COP(=O)(NC(C)C(=O)OC(C)C)Oc2ccccc2)C(O)C1(C)F.CNc1nc(N)nc2c1ncn2C1OC(COP(=O)(NC(C)C(=O)OC(C)C)Oc2ccccc2)C(O)C1(C)F.O=S(=O)(O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 40
Group description: Part A

AT-527: One 550 mg tablet of AT-527 administered every ~12 hours (twice a day) for a total of 5 days
Eligibility criteria:
Key Inclusion Criteria:

Hospitalized or in a hospital-affiliated confinement facility
SARS-CoV-2 positive
Initial COVID-19 symptom onset within 5 days prior to Screening
SpO2 ≥ 93% on room air or requires ≤ 2L/min oxygen by nasal cannula or mask to maintain SpO2 ≥ 93%
Must also have a history of at least one of the following known risk factors for poor outcomes: obesity (BMI>30), hypertension, diabetes or asthma.

Key Exclusion Criteria:

Severe or critical COVID-19 illness: RR ≥30, HR ≥125, SpO2 <93% on room air or requires >2L/min oxygen by nasal cannula or mask to maintain SpO2 ≥93%, systolic blood pressure < 90 mm Hg, diastolic blood pressure < 60 mm Hg or PaO2/FiO2 <300
Requires mechanical ventilation
Lobar or segmental consolidation on chest imaging.
Treatment with other drugs thought to possibly have activity against SARS-CoV-2
ALT or AST > 5 x upper limit of normal (ULN)
Female subject is pregnant or breastfeeding
Has received or is expected to receive any dose of a SARS-CoV-2 vaccine before the Day 14 visit (Part B).
Intervention: Ethanol
Trial phase: Phase 2
ATC code: D08AX08 | V03AB16 | V03AZ01
SMILES: CCO
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 28
Group description: Participants in this group will receive 2 sessions of autologous PRP penile injection, each administered 1 month apart ± 7 days

Autologous Platelet Rich Plasma: Each injection session will consist of a total of 5 mL PRP infused slowly over a 2-minute period; 2.5 mL each injected to the right and left corpus cavernosum.
Eligibility criteria:
Inclusion Criteria:

Be Male
Be 30 to 75 years of age (inclusive).
Be able to provide written informed consent.
Have a diagnosis of ED due to organic origin for at least 6 months prior to consent.
Sexually active in a stable, heterosexual relationship of more than three months duration.
IIEF-EF score 11-25 at screening (even if taking a single PDE5).
Agree to attempt sexual intercourse at least 4 times per month for the duration of the study without being under the influence of alcohol or recreational drugs.
Agree to comply with all study related tests/procedures.

Exclusion Criteria:

Previous penile surgery of any kind (except circumcision and condyloma removal), such as penile lengthening, penile cancer surgery, penile plication, grafting.
Previous history of priapism or penile fracture
Abnormal morning serum testosterone level defined as a value lower than 300 ng/dL (±5%) (indicative of untreated hypogonadism), or greater than 1197 ng/dL (±5%).
Current or previous hormone usage, other than prescribed testosterone, clomiphene or thyroid medication. (Subjects with prior or current use of hormonal treatment for prostate cancer are also excluded.
Psychogenic ED as determined by study investigator.
Anatomical (Peyronie's Disease or penile curvature that negatively influences sexual activity) or neurological abnormalities in the treatment area.
Patients using Intra Cavernous Injection (ICI)for management of ED
Patients with generalized polyneuropathy, or neurological conditions irrespective of cause, such as severe diabetes, multiple sclerosis or Parkinson's disease.
Have a serious comorbid illness/condition/behavior that, in the opinion of the investigator, may compromise the safety or compliance of the subject or preclude successful completion of the study.
History of consistent treatment failure with PDE5 inhibitors for therapy of ED.
Any history of significant psychiatric disease, such as bipolar disorder or psychosis, greater than one lifetime episode of major depression, current depression of moderate or greater severity. Patients who are currently using Selective Serotonin Reuptake Inhibitor or psychotropic medications.
Hemoglobin a1c >9%.
Intervention: Lorcaserin hydrochloride
Trial phase: Phase 2
SMILES: CC1CNCCc2ccc(Cl)cc21.Cl
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 5
Group description: Lorcaserin (10mg BID)

Lorcaserin Oral Tablet: Lorcasering 10mg Oral Tablet (BID)
Eligibility criteria:
Inclusion Criteria:

Age 21-65
Meeting DSM-5 criteria for current (past year) AUD, as well as current at-risk drinking (i.e., ≥14/21 drinks per week for women/men, on average), with at least four episodes of 4+/5+ drinks in the past 30 days
Daily smoker, defined as reporting smoking 1+ cigarettes per day, on average, over the past 12 months
Willingness to take study pills and complete study procedures
Willingness to complete lab sessions involving alcohol administration

Exclusion Criteria:

Recent (30 day) illicit drug use (with the exception of cannabis) based on self-report or toxicology screen
Meeting DSM-5 criteria for a past-year substance use disorder other than alcohol use disorder, tobacco use disorder, or mild cannabis use disorder
Significant alcohol withdrawal, based on a Clinical Institute Withdrawal Assessment for Alcohol-revised (CIWA-Ar) score of 8+ at baseline medical visit, or any reported history of severe withdrawal symptoms (e.g., seizures)
Past 30-day use of nicotine replacement
Past 30-day use of SSRIs, other psychiatric medications, or weight control medications
Lifetime diagnosis of severe mental illness (e.g., psychotic or bipolar I disorder)
Significant medical or neurological illness based on medical staff (i.e., physician or nurse practitioner) evaluation including severe hepatic impairment or cirrhosis, insulin dependent diabetes
Current alcohol or smoking cessation treatment or efforts to cut down on drinking/smoking
Medications contraindicated for use with lorcaserin or which have a significant interaction with lorcaserin
Body mass index (BMI) under normal range (<18kg/m2)
History of significant cardiovascular conditions including history of arrhythmias or heart block, heart failure, valvular heart disease, heat attack, stroke, unstable angina
Abnormal electrocardiogram (ECG) results
Currently nursing, pregnant, or anticipating pregnancy
history of suicide attempt or recent suicidal ideation (i.e., Suicidal thoughts (intent or plan) in the last month)
Plans to travel outside of the local area during the study period, or inability to commit to entire duration of study
Intervention: Formocresol
Trial phase: Phase 4
SMILES: C.C=O.O.c1ccccc1
Sex: All
Age groups: Child
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 30
Group description: Formocresol was used as a medicament to cover root stumps of asymptomatic thirty primary molars with vital pulp exposures. Teeth were followed up clinically and radiographically for 12 months.

Formocresol: Pulpotomy
Eligibility criteria:
Inclusion Criteria:

healthy, cooperative children
mandibular primary molars with vital pulp exposures

Exclusion Criteria:

clinical or radiographic evidence of irreversible pulpitis
physiological root resorption
Intervention: Hydromorphone
Trial phase: Phase 4
ATC code: N02AA03 | N02AA53 | N02AG04
SMILES: [H][C@@]12CCC(=O)[C@]3([H])Oc4c(O)ccc5c4[C@]13CCN(C)[C@]2([H])C5
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 1
Group description: Administered at a dose of 1 mg over 5 minutes

HYDROmorphone Injection: 1 mg over 5 minutes
Eligibility criteria:
Inclusion Criteria:

Must be a patient in the emergency department (ED)
Must have acute abdominal pain, defined as abdominal or flank pain of a duration of 7 days or less
Predicted treatment must include the use of an intravenous opiate

Exclusion Criteria:

Cardiac conduction system impairment (QTc duration > 0.5s, QRS duration > 0.12s, PR interval <0.12s or > 0.2s)
Known renal (CKD >2) or liver disease (Childs-Pugh B or greater)
Hemodynamically instability, defined by the attending physician
Pregnant or breastfeeding
Have a known allergy to either medication
Used of prescription or illicit opioids within the previous week
Patients with a chronic pain disorder, defined as use of any analgesic medication on more days than not during the four weeks preceding the acute episode of pain
Intervention: Niclosamide
Trial phase: Phase 2
ATC code: P02DA01
SMILES: O=C(Nc1ccc([N+](=O)[O-])cc1Cl)c1cc(Cl)ccc1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 33
Group description: Participants received Niclosamide 2 grams by mouth daily for 7 days.
Eligibility criteria:
Inclusion Criteria:

Positive SARS-CoV-2 test by PCR
No requirement of oxygen supplementation
Ability to take oral medication

Exclusion Criteria:

Known allergic reactions to any components of Niclosamide medication
Participation in another trial or use of any experimental treatment for COVID-19, including chloroquine, hydroxychloroquine, remdesivir, and lopinavir/ritonavir
Hospitalization or requirement of hospitalization at the time of enrollment
Intervention: Lovenox
Trial phase: Phase 3
SMILES: CC(=O)NC1C(O)OC(COS(=O)(=O)O)C(OC2OC(C(=O)O)C(OC3OC(CO)C(OC4OC(C(=O)O)C(O)C(O)C4OS(=O)(=O)O)C(OS(=O)(=O)O)C3NS(=O)(=O)O)C(O)C2OS(=O)(=O)O)C1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 129
Group description: Subjects in this study arm will be treated with therapeutic doses of subcutaneous low-molecular-weight heparin (enoxaparin). Enoxaparin 1mg/kg SQ BID for CrCl ≥ 30ml/min (or Enoxaparin 0.5mg/kg SQ BID for CrCl ≥ 15ml/min and < 30ml/min) during the course of their hospitalization.

Enoxaparin: Full Dose LMWH anticoagulation therapy
Eligibility criteria:
Inclusion Criteria:

Subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures.
Understands and agrees to comply with planned study procedures.
Male or non-pregnant female adult ≥18 years of age at time of enrollment.
Subject consents to randomization within 72 hours of hospital admission or transfer from another facility within 72 hours of index presentation.
Subjects with a positive COVID-19 diagnosis by nasal swab or serologic testing.
Hospitalized with a requirement for supplemental oxygen.

Have:

Either a D- Dimer > 4.0 X ULN, OR
Sepsis-induced coagulopathy (SIC) score of ≥4

Exclusion Criteria:

Indications for therapeutic anticoagulation

Absolute contraindication to anticoagulation including:

active bleeding,
recent (within 1 month) history of bleed,
dual (but not single) antiplatelet therapy,
active gastrointestinal and intracranial cancer,
a history of bronchiectasis or pulmonary cavitation,
Hepatic failure with a baseline INR > 1.5,
CrCl < 15ml/min,
a platelet count < 25,000,
a history of heparin-induced thrombocytopenia (HIT) within the past 100 days or in the presence of circulating antibodies,
contraindications to enoxaparin including a hypersensitivity to enoxaparin sodium, hypersensitivity to heparin or pork products, hypersensitivity to benzyl alcohol,
pregnant female,
inability to give or designate to give informed consent,
participation in another blinded trial of investigational drug therapy for COVID-19
Intervention: Lovenox
Trial phase: Phase 3
SMILES: CC(=O)NC1C(O)OC(COS(=O)(=O)O)C(OC2OC(C(=O)O)C(OC3OC(CO)C(OC4OC(C(=O)O)C(O)C(O)C4OS(=O)(=O)O)C(OS(=O)(=O)O)C3NS(=O)(=O)O)C(O)C2OS(=O)(=O)O)C1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 124
Group description: Subjects in this study arm will be treated with Local institutional standard-of-care for prophylactic-dose or intermediate-dose UFH or LMWH. Regimens allowed are UFH up to 22,500 IU daily in BID or TID doses (i.e. UFH 5000 IU SQ BID/TID or 7500 IU BID/TID), enoxaparin 30mg and 40mg SQ QD or BID (the use of weight-based enoxaparin i.e. 0.5mg/kg SQ BID for this arm is acceptable but strongly discouraged), dalteparin 2500IU or 5000IU QD.

Prophylactic/Intermediate Dose Enoxaparin: Prophylactic/Intermediate Dose LMWH or UFH therapy
Eligibility criteria:
Inclusion Criteria:

Subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures.
Understands and agrees to comply with planned study procedures.
Male or non-pregnant female adult ≥18 years of age at time of enrollment.
Subject consents to randomization within 72 hours of hospital admission or transfer from another facility within 72 hours of index presentation.
Subjects with a positive COVID-19 diagnosis by nasal swab or serologic testing.
Hospitalized with a requirement for supplemental oxygen.

Have:

Either a D- Dimer > 4.0 X ULN, OR
Sepsis-induced coagulopathy (SIC) score of ≥4

Exclusion Criteria:

Indications for therapeutic anticoagulation

Absolute contraindication to anticoagulation including:

active bleeding,
recent (within 1 month) history of bleed,
dual (but not single) antiplatelet therapy,
active gastrointestinal and intracranial cancer,
a history of bronchiectasis or pulmonary cavitation,
Hepatic failure with a baseline INR > 1.5,
CrCl < 15ml/min,
a platelet count < 25,000,
a history of heparin-induced thrombocytopenia (HIT) within the past 100 days or in the presence of circulating antibodies,
contraindications to enoxaparin including a hypersensitivity to enoxaparin sodium, hypersensitivity to heparin or pork products, hypersensitivity to benzyl alcohol,
pregnant female,
inability to give or designate to give informed consent,
participation in another blinded trial of investigational drug therapy for COVID-19
Intervention: Dapagliflozin Propanediol
Trial phase: Phase 1 | Phase 2
SMILES: CC(O)CO.CCOc1ccc(Cc2cc(C3OC(CO)C(O)C(O)C3O)ccc2Cl)cc1.O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 20
Group description: 10 participants with pre-diabetes will be randomized to the experimental group to receive dapagliflozin 10mg by mouth daily for 12 weeks.

Dapagliflozin 10 mg: 10 participants randomized to receive 12 weeks of daily dapagliflozin 10mg by mouth
Eligibility criteria:
Inclusion Criteria:

Men or post-menopausal women.
Age= 60+ years.
All ethnic groups.
Body Mass index (BMI) between 30-38 kg/m2.
Diagnosis of pre-diabetes (HbA1c 5.7-6.4% and 2 hr. Oral Glucose Tolerance Test (OGTT) glucose between 140-199 mg/dL, evaluated at Visit 1 and 2).
Stable body weight (±3% for ≥3 months).
Willing to adhere to medication regimen for three months.
Montreal Cognitive Assessment score ≥21

Exclusion Criteria:

Diagnosis of diabetes based on American Diabetes Association (ADA) criteria
Impaired renal function with estimated Glomerular Filtration Rate (eGFR) < 45 mL/min/1.73m2 .
Impaired liver function with labs ≥3 times upper limits of normal range
Abnormal hematocrit with lower limits of ≤30%
Abnormal triglycerides with upper limits ≥600 mg/dL
Abnormal Thyroid stimulating hormone (TSH) values ≤0.3 and ≥10
Urinalysis results with ˃ 5-10 white blood cell count
Concomitant medications known to affect glucose and lipid homeostasis (anti-diabetes medications, glucocorticoids, atypical antipsychotics, anti-transplant rejection medications, anti-retrovirals).
Current treatment with anticoagulants (warfarin). Aspirin (up to 325 mg) and clopidogrel will be permitted if these can be held for seven days prior to the biopsies.
History of recent cardiovascular event in the last 6 months or Heart Failure (New York Heart Classification greater than class III-IV; recent EKG changes that suggest active heart disease
Poorly controlled blood pressure (systolic BP>180, diastolic BP>100 mmHg).
Active inflammatory, autoimmune, infectious, hepatic, gastrointestinal, malignant, and uncontrolled psychiatric disease (Subjects with depression, anxiety, PTSD, etc. can enroll if controlled and on stable medication)
Blood donation within 2 months prior to enrollment
History of frequent UTI
Intervention: Varenicline
Trial phase: Phase 2
ATC code: N07BA03 | S01XA28
SMILES: c1cnc2cc3c(cc2n1)C1CNCC3C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 34
Group description: 0.5 mg PO BID varenicline for 3 weeks (beginning with a 0.25 mg dose and escalated over the next 2 days)
Eligibility criteria:
Inclusion Criteria:

PD diagnosis will be based on the United Kingdom Parkinson's Disease Society Brain Bank Research Center (UKPDSBRC) clinical diagnostic criteria. The investigators will enrich the cohort by recruiting subjects at modified Hoehn and Yahr stages 2 or higher, duration of motor disease 5 years or longer, age >65 years, or the Postural Instability and Gait Disorder (PIGD) phenotype. Duration of motor disease will be defined as the time between onset of motor symptoms and time of entry into the study. The PIGD phenotype is defined as described previously. PD subjects with defined cholinergic deficits will be recruited as described in Project II. PD subjects will have cortical cholinergic deficits based on 5th percentile cutoff of the normal controls as defined previously.
Stable dopaminergic replacement therapy for 3 months prior to enrollment and expected to maintain stable dopaminergic therapy for duration of study participation.

Exclusion Criteria:

Other disorders which may resemble PD with or without dementia, such as vascular dementia, normal pressure hydrocephalus, progressive supranuclear palsy, multiple system atrophy, corticobasal ganglionic degeneration, or toxic causes of parkinsonism. Prototypical cases have distinctive clinical profiles, like vertical supranuclear gaze palsy, early and severe dysautonomia or appendicular apraxia, which may differentiate them from idiopathic PD. The use of the UKPDSBRC clinical diagnostic criteria for PD will mitigate the inclusion of subjects with atypical parkinsonism and all participants will undergo [11-Carbon]dihydrotetrabenazine PET to confirm striatal dopaminergic denervation.
Subjects on neuroleptic, anticholinergic (trihexphenidyl, benztropine), or cholinesterase inhibitor drugs.
Current or previous (within last 6 months) use of any product or medication containing nicotinic agents,including use of tobacco products such as cigarettes, cigars, pipes, chewing tobacco, etc., electronic cigarettes, over-the-counter nicotine patches, chewing gum containing nicotine, or varenicline.
Evidence of a stroke or mass lesion on structural brain imaging (MRI).
Participants in whom magnetic resonance imaging (MRI) is contraindicated including, but not limited to, those with a pacemaker, presence of metallic fragments near the eyes or spinal cord, or cochlear implant.
Severe claustrophobia precluding MR or PET imaging
Subjects limited by participation in research procedures involving ionizing radiation.
Pregnancy (test within 48 hours of each PET session) or breastfeeding.
Significant risk of cardiovascular event.
Active, significant mood disorder.
Intervention: Dihydroergotamine
Trial phase: Phase 3
ATC code: N02CA01 | N02CA51
SMILES: [H][C@@]12Cc3c[nH]c4cccc(c34)[C@@]1([H])C[C@@H](C(=O)N[C@]1(C)O[C@]3(O)N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1CCC[C@]13[H])CN2C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 446
Group description: Subjects received a single oral dose of STS101 (dihydroergotamine nasal powder) 5.2 mg.
Eligibility criteria:
Key Inclusion Criteria:

Males or females, 18-65 years of age at the time of Screening Visit
Subject has at least 1-year history of migraines (with or without aura), according to the
International Classification of Headache Disorder, 3rd Edition (ICHD3)

Key Exclusion Criteria:

Pregnant or breast-feeding women
Women of child-bearing potential not using or not willing to use highly effective contraception.
Diagnosis of headache conditions other than migraine with or without aura, including diagnosis of basilar or hemiplegic migraines or cluster headache.
History of coronary artery disease, coronary artery vasospasm (including Printz-metals' angina), clinically significant arrhythmia or, peripheral vascular disease, ischemic disease (e.g. Raynaud's syndrome, ischemic bowel syndrome, angina pectoris, myocardial infarction, or documented silent ischemia); percutaneous coronary intervention, or cardiac surgery.
History of cerebrovascular disease, including but not limited to stroke, transient ischemic attack, cerebral hemorrhage, subarachnoid hemorrhage.
Diagnosis of major depression with current symptoms, psychosis, alcohol abuse or dependence, drug abuse or dependence, major psychiatric conditions (e.g. schizophrenia, psychosis or Bipolar disorder), dementia. Other significant neurological or psychiatric disorders (including other pain syndromes or risk of suicide) that in the opinion of the investigator might interfere with study participation and assessments or subject safety.
Any clinically significant symptoms or conditions, including but not limited to central nervous system (e.g., seizures), cardiac, pulmonary, metabolic, renal, hepatic or gastrointestinal conditions or history of such conditions that, in the opinion of the investigator might interfere with study assessments or safety of participant.